Starting with the 2021, Juvenile Tissue Citrus Transformation Facility (JTCTF) started operating as an EBA unit. As a result of this transition, relationship between the clients and JTCTF is redefined in a sense that clients will be paying for the work JTCTF has done and not for the produced plants. Towards this goal, JTCTF has created a price list for the services it offers. In accordance with changed status of JTCTF, administration at CREC has established an account that will be used for financial transaction associated with facility’s operation. In the first three months of 2021, Juvenile Tissue Citrus Transformation Facility (JTCTF) accepted five new orders. Four of those orders were for transgenic sweet orange plants and one for Duncan grapefruit plants. One of the orders is associated with the existing USDA grant, while four other orders will be paid for. Certain number of orders that were expected because JTCTF was designated subcontractor have not materialized because those clients have not started working on projects for which they received funding as they had difficulties in hiring personnel.At this time, JTCTF has four employees but one has not worked since December of 2020 because of unresolved immigration status. Another employee is working during the night which has allowed us to return to the level of attendance of pre-COVID period. As a result, the facility operated at about 75% capacity. Between January and April, JTCTF produced 10 plants. Those include five Duncan grapefruit plants transformed with HGJ87 and HGJ88 plasmids. The rest are sweet orange plants transformed with pXH-H1 and pXH-H2 plasmids.